secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0001193125-22-258534
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics updates epetraborole development; Phase 1 Japan study supports 500 mg dose; EU orphan designation
--------------------------------------------------------------------------------

- Phase 1 study in Japanese volunteers (EBO-103) showed no adverse events, supports once-daily 500 mg dose for Phase 2/3.
- Epetraborole exposures similar across ADH genotypes and consistent with prior Phase 1 study in non-Japanese subjects.
- EU Commission granted orphan medicinal product designation for epetraborole in NTM lung disease.
- Company plans to initially focus clinical development for treatment-refractory MAC lung disease on Japan and the U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/0001193125-22-258534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312522258534/d383473d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-258534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer